Mast cells as predictors of bladder cancer

DOI: https://doi.org/10.29296/25877305-2022-09-11
Issue: 
9
Year: 
2022

Professor T. Pavlova(1), MD; D. Atyakshin2, MD; I. Pavlov(1), Candidate of Medical Sciences; D. Bessmertnyi(1), Candidate of Medical Sciences; Professor
N. Pilkevich(1), MD; K. Proshchaev(1), MD
1-Belgorod State National Research University
2-Research Institute of Experimental Biology and Medicine, N.N. Burdenko Voronezh State Medical University

Objective. To investigate mast cell populations in patients of different ages with Stage II–III bladder cancer (BC), by using innovative immunohistochemical approaches (to study chymase and thymase of positive structures). Subjects and methods. Immunohistochemical approaches were used to examine material from 25 patients: a study group of 20 patients with histologically verified Stage II–III bladder cancer; a control group of 5 men aged 36–50 years without cancer who died in traffic accidents. Results. The investigation of the protease profile of a mast cell population in the bladder showed that during the process of cancer development, the time course of changes in the content of protease-positive mast cells was different: the number of tryptase-positive mast cells increased, while that of chymase-positive mast cells significantly decreased. An analysis of the protease profile indicated that with the process of cancer development, mast cell chymase expression noticeably decreased; the size of mast cells in the connective tissue subpopulation reduced. However, they could form local intraorganic accumulations, secreting both tryptase and chymase in fairly immense areas.
Keywords: 
oncology
cancer
bladder
mast cells
elderly age

References: 
  1. Pristrom M.S., Pristrom S.L., Semenkov I.I. Physiological and early aging. Modern view of the problem. Medical news. 2015; 2: 36–45 (in Russ).
  2. Oncogerontology. Guide for doctors. Ed. V.N. Anisimova, A.M. Belyaev. St. Petersburg: Publishing house ANNMO «Issues of oncology», 2017; 509 (in Russ.).
  3. Malignant neoplasms in Russia in 2020 (morbidity and mortality). Ed. A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadov. M.: MNIOI im. P.A. Herzen – a branch of the Federal State Budgetary Institution «NMITs Radiology» of the Ministry of Health of Russia, 2021; 252 р. (in Russ).
  4. Pavlova T.V., Pilkevich N.B., Bessmertny D.V. et al. Features of metabolic atypism during the development of oncological pathology of the urogenital system. Molecular medicine. 2021; 19 (31): 30–4 (in Russ.). DOI: 10.29296/24999490-2021-01-04
  5. Clinical recommendations. Bladder cancer. Coding according to the International Statistical Classification of Diseases and Related Health Problems: C67. Age group: adults. 2020; 81 р. (in Russ).
  6. Bukhvalov I.B., Atyakshin D.A., Pavlova T.V. et al. Histochemistry. Voronezh: Scientific book, 2018; 238 р. (in Russ).
  7. Pavlova T.V., Kulikovsky V.F., Pavlova L.A. Clinical and experimental morphology. M.: OOO Medical Information Agency, 2018; 256 р. (in Russ).
  8. Buchwalow, I.B., Boecker W. Immunohistochemistry: Basics and Methods, 1st ed. Berlin, Heidelberg (Germany), Dordrecht (Netherlands), London (UK), New York (USA): Springer, 2010; 152 р.
  9. Atiakshin D.A., Shishkina V.V., Gerasimova O.A. et al. Combined histochemical approach in assessing tryptase expression in the mast cell population. Acta Histochem. 2021; 123: 151–71. DOI: 10.1016/j.acthis.2021.151711